Skip to main content
. 2017 Mar 3;174(8):700–717. doi: 10.1111/bph.13731

Figure 9.

Figure 9

Diagram of the actions and mechanisms of IM in the present study. Imatinib inhibits the expression of PXR, leading to the suppressed expression of CESs, as well as other PXR target genes, CYP3A4 and P‐gp. The findings of the present study are highly relevant to the assessment of potential drug–drug interactions (DDI) in the clinical therapy of CML.